

AD _____

Award Number: W81XWH-09-1-0276

TITLE: Therapeutic Remyelination Strategies in a Novel Model of Multiple Sclerosis:
Japanese Macaque Encephalomyelitis

PRINCIPAL INVESTIGATOR: Larry S. Sherman

CONTRACTING ORGANIZATION: Oregon National Primate Research Center
Oregon Health & Science University
Beaverton, OR 97006

REPORT DATE: May 2011

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE May 2011		2. REPORT TYPE Annual		3. DATES COVERED 1 May 2010 – 30 April 2011	
4. TITLE AND SUBTITLE Therapeutic Remyelination Strategies in a Novel Model of Multiple Sclerosis: Japanese Macaque Encephalomyelitis				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-09-1-0276	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Larry S. Sherman, Scott Wong, Betsy Ferguson, William Rooney E-Mail: shermanl@ohsu.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Oregon National Primate Research Center Oregon Health & Science University Beaverton, OR 97006				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT During the second year of this grant, we have finished characterizing the spontaneous form of Japanese macaque encephalomyelitis (JME) and published a manuscript in Annals of Neurology describing our results; we have characterized how intracranial injections of the Japanese macaque rhadinovirus (JMRV) induce demyelinating disease, as assessed by histopathology, MRI, and symptoms; we have demonstrated both in vitro and in vivo which cells are affected by JMRV infection; we have performed additional analyses characterizing the immune response to JMRV infection; and we have continued our genetic analyses. In the next year, we will continue to analyze the mechanisms by which JMRV triggers disease onset and immune responses and the role of the cytopathic effects of the virus in this process, which genes are linked to disease susceptibility, and how the virus influences cells in lesion microenvironments.					
15. SUBJECT TERMS multiple sclerosis, Japanese macaque, demyelination, virus, major histocompatibility complex					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			USAMRMC
U	U	U	UU	20	19b. TELEPHONE NUMBER (include area code)

Table of Contents

	<u>Page</u>
Introduction.....	2
Body.....	3
Key Research Accomplishments.....	5
Reportable Outcomes.....	6
Conclusion.....	6
References.....	6
Appendices.....	7

Particular viruses, especially gamma-herpesviruses, may act as a trigger of multiple sclerosis (MS) (Levin et al., 2010; Ascherio and Munger, 2010). Furthermore, there is growing evidence that susceptibility to MS may be linked to polymorphisms at certain genetic loci, including major histocompatibility complex (MHC) genes and the interleukin-7a gene (Ramagopalan et al., 2009; Harley, 2007). This study is a collaborative effort between several investigators at the Oregon National Primate Research Center (ONPRC) who are interested in understanding the pathophysiological mechanisms that trigger MS and related inflammatory demyelinating disease. We have characterized a novel encephalomyelitis that occurs spontaneously in a small percentage of animals in a colony of Japanese macaques (JMs) at the ONPRC. The disease, called Japanese macaque encephalomyelitis (JME), occurs in both progressive and relapsing-remitting forms and is characterized by brain and spinal cord demyelination that is accompanied by extensive astrogliosis. Affected animals develop debilitating motor and ocular disturbances. Approximately 10% of the animals in this colony appear to have chronic, subclinical lesions as evaluated by magnetic resonance imaging (MRI). Pedigree analysis indicates that particular lineages of animals are substantially more susceptible to this disease than others, suggesting a genetic pre-disposition to JME. Furthermore, we have cloned a gamma-herpesvirus (called Japanese macaque rhadovirus; JMRV) from animals in this colony that is found within demyelinated JME lesions.

This highly integrated, multidisciplinary application is focused on developing JME as a pathophysiological and genetic model of MS whose etiology and progression more closely resemble MS in humans than other EAE and viral models in non-human primates and rodents. We aim to use this model to better understand how gamma-herpesviruses trigger MS; whether polymorphisms in gene loci that have been linked to MS in humans also predispose JMs to JME; to evaluate the lesions in both symptomatic and subclinical animals to determine if they model numerous aspects of human MS lesions; and to test if gamma-herpesvirus infection directly influences astrogliosis and the accumulation of factors, such as hyaluronan, that can inhibit remyelination in demyelinated lesions. Our long-term goal is to develop JME as a model for testing immunological and neurobiological processes underlying MS, and to use this model in pre-clinical screens of novel agents with the potential to inhibit MS attacks and to promote remyelination and regeneration.

The second year of the project has been focused on the following areas:

1. Further characterizing the effects of intracranial JMRV infections on Japanese macaques from previously affected and unaffected lineages
2. Characterizing the cytopathic effects of JMRV infections
3. Characterizing the immunological responses to JMRV infection
4. Characterizing the genetic liability to the disease

Our progress in these areas is outlined below.

Body

Aim 1: To test the hypothesis that intracranial infection with Japanese macaque rhadovirus (JMRV) can experimentally induce Japanese macaque encephalomyelitis (JME)

We have experimentally inoculated a total of 29 animals through year 2 of the award. Each of the animals received a series of MRIs pre- and post-infection to document and assess the inflammatory response to intracranial inoculation (i.c.). The animals were separated into two groups based upon whether they were genetic or observed 1st order relatives (related, n=17) of animals that developed spontaneous JME or non-related animals (not related, n=12). The extent of the inflammatory response in the white matter (wm) as determined by hyperintensive T₂-weighed signal, was calculated volumetrically as percent wm affected and is presented as line graphs of related and not related (Figure 1A).




Figure 1: Comparison of affected WM following intracranial JMRV infection in 1st order relatives of spontaneous JME affected animals versus non-related animals. Percent of WM affected from each animal in the related or not related was determined and the mean for each group was calculated at each time post-infection (week) along with the standard deviation.

By this analysis we found that related animals achieved a statistically significant ($p \leq 0.0001$) increase in T₂-weighted signal in the wm compared to animals that were not-related at 1 week post-infection. These findings suggest that the animals possess inherent differences and that these differences are associated with virus infection as there was no difference in T₂-weighed signal by vehicle injection alone (Figure 2). These results are consistent with what we observed in our previous progress report and are now substantiated by biostatistical analysis.




Figure 2: Comparison of affected white matter (WM) following intracranial sham virus infection (PBS alone) in 1st order relatives of spontaneous JME affected animals versus non-related animals. Percent of WM affected from each animal in the related or not related was determined and the mean for each group was calculated at each time post-infection (week) along with the standard deviation.

Since the related animals reacted differently than the not related animals, we investigated whether the animals differed in their T cell-mediated immune response to JMRV infection. To accomplish this, we performed intracellular cytokine staining (ICCS) assays on peripheral mononuclear cells (PBMCs) isolated at different times post-infection that were consistent with MRI analysis. For this assay, isolated PBMCs are infected with JMRV in vitro and subsequently stained for interferon gamma (IFN γ) and for T cell subset analysis (CD4 or CD8+ T cells). By this analysis we found striking differences in CD4 (Figure 3A) and CD8 (Figure 3B) T cell responses to JMRV infection between related and not related animals. Specifically, JMRV-specific CD4+ and CD8+ T cell responses were detected earlier (3 weeks) in related animals than not related animals.




Figure 3: Comparison of CD4+ (A) and CD8+ (B) T cell responses to JMRV infection in related versus non-related animals. Percent of CD4 or CD8 T cells responding to JMRV infection was determined by ICCS and flow cytometry. The mean for each group was calculated at each time post-infection (week) and plotted along with the standard deviation.

Overall, these results are consistent with what we reported last year in a small group of animals and further support our hypothesis that experimental intracranial inoculation of Japanese macaques with JMRV can precipitate inflammatory response which can lead to inflammatory demyelination. We are currently evaluating the myelin oligodendrocyte glycoprotein (MOG) responses in these groups to determine if there are differences between related and non-related animals. Similarly, we are investigating the genetic differences between the two groups, which is described in Aim 2.

Aim 2: Test the hypothesis that common genetic variants in the JM genome increase the susceptibility of developing demyelinating disease.

Previously we began investigating potential associations between MHC haplotype and JME susceptibility, using classic genetic methods to broadly characterize MHC diversity in the Japanese macaque. We used a set of 14 linked microsatellite/short tandem repeat (STR) markers that span the entire MHC locus in macaques. We have now completed the DNA analysis of 280 Japanese macaques, including 28 clinically JME affected animals, and 7 animals without clinical symptoms but with evidence for brain lesions by MRI analysis (MRI+). The STR genotypes revealed 24 different haplogroups, each carrying the same STR alleles throughout the MHC locus. Recombination was detected in less than 10% of animals, and always occurred between a flanking marker and the MHC genes. Only 13 of the 24 MHC possible haplogroups were carried by JME affected animals; haplogroups 1 and 17, had a suggestive association with JME affected status (Figure 1).

We have now also advanced the MHC studies by using RNA sequencing (RNAseq) to identify expressed alleles within the 24 discovered haplogroups. The primary focus of this study is the Class II DRB locus, due to the reoccurring linkage of *HLA-DRB* alleles to human MS. RNAseq of 26 individuals thus far provide data on 15 of the 24 haplogroups (Table 1). The analysis identified 11 new *Mafu-DRB* alleles and extended 7 previously found *Mafu-DRB* alleles. This study also showed that there are some allele expression differences within 3 haplogroups (8, 15/17), suggesting that higher resolution analysis will be important for the identification of haplotype associations with JME. Alleles of interest currently include *DRB*014*, *DRB*015*, *DRB*016* and *DRB*017*, although additional studies including more individuals and full MHC expression analysis will be required. Nonetheless, these approaches are the first of their kind for the analysis of MHC allele diversity of Japanese macaques, and show promise for providing the allelic resolution necessary to test associations between MHC haplotypes and JME susceptibility.




Figure 4. Distribution of 24 MHC haplogroups, by portion of chromosomes within JME cases and non-affected individuals.

Table 1. Expressed JM DRB alleles

STR	Mafu-DRB
11, 13	DRB*001:nov:01 DRB*003:nov:01
15*,17*	DRB*002:nov:01;DRB1*0302
15, 17	DRB*014:nov:01 DRB*015:nov:01
4, 9	DRB*004:nov:01;DRB*W303
8*	DRB*005:nov:01 DRB*006:nov:01
5, 6, 19	DRB*001:nov:02;DRB*W102 DRB*008:nov:01
10	DRB*009:nov:01; DRB1*0302
12	DRB*009:nov:02
18	DRB*010:nov:01; DRB1*1002
7	DRB*011:nov:01 DRB*012:nov:01
8	DRB*013:nov:01
1	DRB*016:nov:01; DRB1*W1001 DRB*017:nov:01; DRB*W401

Aim 3: To test the hypothesis that JMRV infection of glial cells directly influences demyelination and remyelination failure.

We characterized the lesions from spontaneous cases of JME to better understand the degrees of myelin and axonal damage. These results were published in *Annals of Neurology* (see appendix). Interestingly, similar to MS patient lesions, we observed a significant decline in the numbers of cells expressing oligodendrocyte cell lineage markers (e.g. olig2). Similar changes have been observed in animals receiving intracranial injections of JMRV.

Using primary cultures of dissociated fetal Japanese macaque cerebral cortex (from protocols established during the first year of the project), we have been able to demonstrate that *in vitro* exposure to JMRV infects microglia, oligodendrocyte lineage cells, and neurons. Preliminary findings suggest that cells in the oligodendrocyte lineage are killed by viral infection, along with some microglia. These studies are on-going.

Key Research Accomplishments

- Determined that intracranial injection of JMRV, even in previously exposed animals, is sufficient to cause an MS-like disease in genetically susceptible Japanese macaques but not in un-related animals
- Determined that JMRV-specific CD4+ and CD8+ T cell responses occur earlier in animals with a genetic liability to JME than in unrelated animals
- Determined that JMRV is cytopathic to cells in the oligodendrocyte lineage
- Fully characterized spontaneous JME lesions

Reportable Outcomes

Axthelm MK, Bourdette DN, Marracci GH, Su W, Mullaney ET, Manoharan M, Kohama SG, Pollaro J, Witkowski E, Wang P, Rooney WD, Sherman LS, Wong SW. Japanese macaque encephalomyelitis: A spontaneous multiple sclerosis-like disease in a nonhuman primate. *Ann Neurol*. 2011 Apr 7. doi: 10.1002/ana.22449.

Conclusion

During the first two years of funding, we have established that JME is an MS-like disease with regards to progression and histopathology; that intracranial infection with JMRV can trigger JME in genetically susceptible animals; that infection is cytopathic to cells in the oligodendrocyte lineage and other cells within demyelinating lesions; that animals that are affected by JMRV have an accelerated immune response following infection; and that there may be specific genetic loci linked to disease liability. Our final goals for this project will be to better understand the mechanisms by which JMRV triggers disease onset and to determine the mechanisms underlying genetic liability to JME.

References

- Ascherio A, Munger KL. Epstein-barr virus infection and multiple sclerosis: a review. *J Neuroimmune Pharmacol*. 2010 Sep;5(3):271-7.
- Harley JB. IL-7Ralpha and multiple sclerosis risk. *Nat Genet*. 2007 Sep;39(9):1053-4
- Levin LI, Munger KL, O'Reilly EJ, Falk KI, Ascherio A. Primary infection with the Epstein-Barr virus and risk of multiple sclerosis. *Ann Neurol*. 2010 Jun;67(6):824-30.
- Ramagopalan SV, Knight JC, Ebers GC. Multiple sclerosis and the major histocompatibility complex. *Curr Opin Neurol*. 2009 Jun;22(3):219-25

Japanese Macaque Encephalomyelitis: A Spontaneous Multiple Sclerosis–like Disease in a Nonhuman Primate

Michael K. Axthelm, DVM, PhD,^{1,2} Dennis N. Bourdette, MD,³ Gail H. Marracci, PhD,³ Weiping Su, PhD,⁴ Elizabeth T. Mullaney, BS,² Minsha Manoharan, MS,² Steven G. Kohama, PhD,⁴ Jim Pollaro, MS,⁵ Ellen Witkowski, BA,⁴ Paul Wang, MD,⁵ William D. Rooney, PhD,⁵ Lawrence S. Sherman, PhD,⁴ and Scott W. Wong, PhD^{1,2,6}

Objective: To describe Japanese macaque encephalomyelitis (JME), a spontaneous inflammatory demyelinating disease occurring in the Oregon National Primate Research Center's (ONPRC) colony of Japanese macaques (JMs, *Macaca fuscata*).

Methods: JMs with neurologic impairment were removed from the colony, evaluated, and treated with supportive care. Animals were humanely euthanized and their central nervous systems (CNSs) were examined.

Results: ONPRC's JM colony was established in 1965 and no cases of JME occurred until 1986. Since 1986, 57 JMs spontaneously developed a disease characterized clinically by paresis of 1 or more limbs, ataxia, or ocular motor paresis. Most animals were humanely euthanized during their initial episode. Three recovered, later relapsed, and were then euthanized. There was no gender predilection and the median age for disease was 4 years. Magnetic resonance imaging of 8 cases of JME revealed multiple gadolinium-enhancing T₁-weighted hyperintensities in the white matter of the cerebral hemispheres, brainstem, cerebellum, and cervical spinal cord. The CNS of monkeys with JME contained multifocal plaque-like demyelinated lesions of varying ages, including acute and chronic, active demyelinating lesions with macrophages and lymphocytic periventricular infiltrates, and chronic, inactive demyelinated lesions. A previously undescribed gamma-herpesvirus was cultured from acute JME white matter lesions. Cases of JME continue to affect 1% to 3% of the ONPRC colony per year.

Interpretation: JME is a unique spontaneous disease in a nonhuman primate that has similarities with multiple sclerosis (MS) and is associated with a novel simian herpesvirus. Elucidating the pathogenesis of JME may shed new light on MS and other human demyelinating diseases.

ANN NEUROL 2011;00:000–000

Multiple sclerosis (MS) is a chronic inflammatory disease that affects the central nervous system (CNS). The disease typically follows a relapsing–remitting course and is associated with a variety of neurological deficits, such as paralysis, imbalance, ataxia, blindness, and ocular motor paresis (reviewed in Noseworthy and colleagues¹). Classically, the pathology of MS consists of discrete, multifocal areas of demyelination, associated with variable axonal loss in the white matter of the brain, spinal cord and optic nerves. More recently, lesions within the gray matter have been described. Lesions with

active demyelination are associated with infiltrating lymphocytes and lipid-laden phagocytic macrophages. Although the cause of MS remains uncertain, there is considerable evidence indicating that multiple genetic loci and incompletely understood environmental exposures influence the risk of developing MS (reviewed in Libbey and colleagues²). One still unproven hypothesis is that a viral infection occurring in genetically susceptible individuals induces the disease.

The most widely studied model of MS is experimental autoimmune encephalomyelitis (EAE) (reviewed

View this article online at wileyonlinelibrary.com. DOI: 10.1002/ana.22449

Received Dec 15, 2010, and in revised form Mar 23, 2011. Accepted for publication Apr 1, 2011.

Address correspondence to Dr Wong, PhD, Vaccine and Gene Therapy Institute, 505 NW 185th Avenue, Beaverton, OR 97006. E-mail: wongs@ohsu.edu

From the ¹Division of Pathobiology and Immunology and ⁴Division of Neuroscience, Oregon National Primate Research Center, Beaverton, OR; ²Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR; ³Neurology and Research Service, Department of Veterans Affairs Medical Center and Department of Neurology, ⁵Advanced Imaging Research Center, and ⁶Department of Molecular Microbiology and Immunology, Oregon Health and Science University, Portland, OR.

in Libbey and colleagues³). This paralytic illness can be induced in a variety of mammalian species by immunization with whole myelin or specific myelin proteins, most notably myelin basic protein (MBP), myelin oligodendrocyte glycoprotein, and proteolipid protein, or peptides from these proteins.^{4–6} Depending on the species used and method of disease induction, EAE can follow a chronic relapsing course and be associated with multifocal areas of demyelination and thus mimic MS pathologically and clinically.⁷ There are also mouse models of virally induced demyelinating diseases, most notably Theiler's murine encephalomyelitis virus (TMEV).^{8–10} TMEV-induced demyelinating disease (TMEV-IDD) is induced by injecting neurotropic strains of the virus into genetically susceptible mice.¹¹ Depending upon the strain of TMEV, infection can result in either acute encephalitis or a chronic immune-mediated multifocal demyelinating disease. While EAE can be induced in rhesus and common marmoset monkeys, a virally induced model of MS has not been described in nonhuman primates (NHPs). Availability of a demyelinating disease associated with a virus in an NHP might prove relevant to understanding the pathogenesis of MS.

Here, we report the spontaneous occurrence of an inflammatory demyelinating disease in a colony of Japanese macaques (JMs, *Macaca fuscata*) at the Oregon National Primate Research Center (ONPRC). The disease, Japanese macaque encephalomyelitis (JME), has clinical and pathologic similarities with MS. Moreover, we report the isolation of a previously undescribed simian herpesvirus isolated from acute JME lesions. This is the first description of a spontaneously occurring MS-like disease in an NHP and has the potential to offer new insights into the pathogenesis of MS.

Subjects and Methods

Animals

All animal procedures were approved by the ONPRC Institutional Animal Care and Use Committee. The ONPRC is an Association for Assessment and Accreditation of Laboratory Animal Care International accredited research facility and conforms to National Institutes of Health guidelines on the ethical use of animals in research. The JM colony is maintained in a 2-acre corral and members of the colony are observed daily for the presence of sick or injured animals. Per institutional protocol, members of the colony developing neurologic dysfunction were removed from the corral, placed in cages, evaluated, and provided supportive care. Most animals developing JME were humanely euthanized per ONPRC protocol. Three animals recovered from their initial episode and were returned to the corral, but later relapsed and were then humanely euthanized.

Clinical Sample Analysis

Cerebrospinal fluid (CSF) was acquired from sedated animals and analyzed for total protein, cell count, and cell type determination. Complete blood count and routine serum chemistries were obtained.

Histopathological Examination

Complete necropsies were performed on all animals. CNS tissues were collected from most animals and either placed in neutral-buffered formalin or neutral-buffered 4% paraformaldehyde for paraffin embedding or media for isolation of a potential infectious agent. Sections from the CNS were cut at 5 μ m, deparaffinized, and stained with hematoxylin and eosin, Luxol fast blue–periodic acid-Schiff (PAS)–hematoxylin stain, or Bielschowsky's silver impregnation to image axons, or blocked with 5% normal goat serum and 5% bovine serum albumin for immunostaining with primary antibodies specific for MBP (rabbit anti-MBP, Zymed, San Francisco, CA; 1:100), neurofilament (NF) light chain (mouse anti-NF, Chemicon, Temecula, CA; 1:500), oligodendrocytes lineage transcription factor 2 (olig2) (rabbit anti-olig2, Chemicon; 1:500), T cells (rabbit anti-CD3, Dako; 1:200), or macrophages (mouse anti-CD68, Dako, Carpinteria, CA; 1:80). Secondary antibodies used were as follows: goat-anti-rabbit immunoglobulin G (IgG) conjugated to Alexa 488 (Molecular Probes, Eugene, OR; 1:500), goat-anti-mouse IgG conjugated to Alexa 546 (Molecular Probes; 1:500), biotinylated goat-anti-rabbit IgG and biotinylated goat-anti-mouse IgG. Streptavidin-Alexa 488 and Streptavidin-Alexa 594 were utilized to visualize CD3+ T cells and CD68+ macrophages, respectively. The sections were then counterstained with 4,6'-diamino-2-phenylindole dihydrochloride (DAPI) (1:5,000) and analyzed by light or fluorescent microscopy performed on a Zeiss (Gottingen, Germany) microscope equipped with an Axiocam digital camera.

For quantitation of olig2-immunolabeled cells, 3 adjacent sections were analyzed at $\times 40$ following double labeling with anti-MBP and anti-olig2 antibodies. Three regions of interest (ROIs) were identified using MBP labeling: the lesion, where MBP immunoreactivity was mostly absent; the border, where there was a mixture of intact myelin and damaged myelin; and adjacent unaffected white matter. The number of olig2+ cells in 3 random microscopic fields within each ROI in each adjacent section was then counted and averaged. The mean differences between ROIs were assessed using Student *t* test.

Magnetic Resonance Imaging

A 4-year 240-day-old female JM exhibiting signs of JME was transported to Oregon Health and Science University Hospital, anesthetized and positioned in a General Electric (Waukesha, WI) 1.5T Signa magnetic resonance imaging (MRI) instrument and T₂-weighted and pregadolinium and postgadolinium T₁-weighted images were obtained from the brain and cervical cord. All other MRIs were performed on a 3T Siemens (Erlangen, Germany) Trio whole-body MRI instrument using a quadrature transmit/receive extremity radiofrequency coil. Sixty sagittally-oriented 2-dimensional (2D) turbo spin echo acquisitions

with proton density (echo time [TE] = 17msec/recycle time [TR] = 9000msec/echo train length [ETL] = 9/number of excitations [NEX] = 1) contrast were collected with a 1mm slice thickness using a 256×256 matrix over a 160mm^2 field-of-view (FOV). Multislice 2D turbo spin echo MRI acquisitions with proton density (TE = 13msec/TR = 9000msec/ETL = 9msec/NEX = 2) and T_2 -weighted (TE = 92msec/TR = 9000msec/ETL = 9/NEX = 2) contrast were collected in an axial orientation angulated parallel to the imaginary line connecting the anterior and posterior commissures; 66 1mm slices were collected using a 320×240 matrix over a $160\text{mm} \times 120\text{mm}$ FOV. Transaxial 3D T_1 -weighted magnetization prepared rapid acquisition gradient echo (MPRAGE); TE = 3.5msec/TR = 2500msec/inversion time [TI] = 900msec/flip angle [FA] = 8) data sets were acquired before and 30 minutes after gadoteridol administration with a $192 \times 144 \times 96$ matrix over a $130\text{mm} \times 98\text{mm} \times 76\text{mm}$ FOV. Gadoteridol was administered in situ at a dose of 0.2mmol/kg using an infusion pump.

Isolation of a Herpesvirus from an Acute Lesion

A spinal lesion from a JM (#17792) with JME was obtained at necropsy, homogenized, and placed over primary rhesus macaque fibroblasts for isolation and analysis of a potential infectious agent as described.¹² Preliminary molecular characterization to identify the herpesvirus was conducted as described.¹² Using the same technique, attempts were made to isolate viruses from other acute JME lesions and normal white matter from JM with and without JME.

Results

JME

The ONPRC has housed an outbred colony of JMs since 1965. No cases of unexplained neurologic disease were observed in the colony prior to 1986. Since 1986, 56 JMs spontaneously developed JME (Fig 1). Currently, 1% to 3% of the colony develops JME each year and the disease affects males and females equally. Except for the burst of cases in August 1987, there is no apparent seasonal predilection and cases have occurred every year since 1986 except in 1993 and 2004. Table 1 provides details of the clinical features of the disease on the 56 cases. The median age of affected animals was 4 years 109 days (range, 97 days–26 years 50 days). The majority of the animals had paresis or paralysis of 1 or more limbs and ataxia. Ocular paresis occurred in 10 cases. Seven animals exhibited other clinical manifestations, including abnormal species-specific behaviors and head tilt accompanied with body tremors. Typically, the onset of clinical disease was acute and progressed rapidly with the median time between presentation of disease to humane euthanasia being 6 days (range, 0 days–121 days). In most cases, euthanasia was required because neurologic impairment made it impossible to return the monkeys safely to the colony. Three animals (#12068,




FIGURE 1: Number of Japanese macaques affected each year with Japanese macaque encephalomyelitis.

21255, and 16749) recovered from their initial episode and were returned to the corral, but were later euthanized when their JME recurred 101 days to 8 years later.

CSF was collected from 40 affected animals. The mean CSF white blood cell (WBC) count was 185 cells/ mm^3 with a range from 0 to 2,710. WBC differential was obtained in 13 cases and in all but 1 the cells consisted of both lymphocytes and neutrophils. The mean total protein was 52mg/dl (range, 0–195mg/dl). Glucose values were normal and attempts to isolate bacteria from CSF were negative. Hematological and biochemical examinations of blood revealed no consistent abnormalities. CSF was not examined for oligoclonal bands or IgG index.

MRI Abnormalities

MRI scans were performed on 8 animals with JME and MRI scans from 3 cases are shown in Figure 2. A brain and cervical MRI scan was performed on JM #19384 11 days after presentation with clinical signs of JME (see Fig 2A–C). Postgadolinium T_1 -weighted images revealed multiple areas of focal contrast enhancement in the white matter of the cerebral hemispheres, cerebellum, brainstem, and cervical spinal cord. JM #26174 underwent MRI 4 days after presentation with acute JME signs (see Fig. 2D–I). The T_2 -weighted axial images in Figure 2D–F showed hyperintense areas in the upper cervical spinal cord, cerebellum, and cerebrum. The axial images of Figure 2G–I show intense focal contrast enhancement in the upper cervical spinal cord, cerebellum, and genu of the corpus callosum. JM #13221 underwent MRI 1 day after presentation with acute JME symptoms (see Fig 2J–L). T_2 -weighted axial images revealed a large hyperintense area in the left cerebral peduncle (see Fig 2J). The same area had a hypointense appearance in the T_1 -weighted MPRAGE image (see Fig 2K). Punctate gadolinium enhancement was apparent in this same peduncle region in the postcontrast T_1 -weighted image (see Fig 2L). The

TABLE 1: Clinical Findings in Cases of JME*

ID#	Sex	Age at Onset (yr/day)	Duration of Disease Prior to Euthanasia (days)	Paresis	Ataxia	Optical	Other	CSF Cells/mm ³ (% lymphocyte/neutrophil)	CSF Protein (mg/dl)
13762	M	1Y76D	6	X				1 (ND)	20
03246	F	20Y17D	61				X		
14871	F	0Y94D	3		X			336 (ND)	0
12800	X ^a	4Y95D	14	X	X	X		186 (ND)	107
14528	X ^a	1Y46D	52		X	X			
14873	M	0Y164D	4			X			
13754	M	2Y104D	2				X	2,710 (ND)	112
07804	F	12Y116D	14		X	X		58 (ND)	0
09179	F	10Y136D	83	X				0 (ND)	11
08234	F	12Y112D	20	X		X		11 (ND)	104
14214	M	2Y64D	0				X		
15535	M	0Y123D	3				X		
13998	M	3Y122D	13		X				
08420	M	13Y19D	4		X			30 (ND)	113
13752	M	3Y336D	3		X				
12113	M	7Y325D	22		X			0 (ND)	22
13768	F	6Y259D	2	X		X		112 (ND)	50
15997	M	1Y336D	1	X				83 (ND)	71
16376	M	0Y327D	2		X			204 (ND)	29
16387	M	1Y235D	7	X				70 (ND)	48
13744	X ^a	7Y185D	6		X			8 (ND)	12
13993	M	6Y337D	0				X		
15306	M	5Y272D	5	X	X	X		12 (ND)	195
12817	F	11Y31D	13	X				20 (ND)	29
11032	F	14Y133D	6				X	68 (ND)	16
12059	F	12Y251D	3		X			10 (ND)	70
17792	M	1Y258D	5	X				385 (ND)	86
16777	M	3Y354D	20		X	X		2 (ND)	10
12068 ^b	M	13Y86D	4	X				174 (ND)	16
18247	M	1Y245D	16	X		X		87 (ND)	39
18925	F	0Y197D	7	X				22 (ND)	21
19325	M	0Y250D	2	X					
19085	F	1Y111D	49	X				58 (ND)	17
19395	F	0Y305D	1		X	X			
16746	F	7Y125D	5	X				20 (ND)	37

TABLE 1 (Continued)

ID#	Sex	Age at Onset (yr/day)	Duration of Disease Prior to Euthanasia (days)	Paresis	Ataxia	Optical	Other	CSF Cells/mm ³ (% lymphocyte/neutrophil)	CSF Protein (mg/dl)
19894	M	1Y220D	0	X					
20472	F	0Y291D	0	X				108 (ND)	50
19400	F	3Y210D	19	X				541 (ND)	144
19384	F	4Y188D	53	X				88 (10/90)	103
16749 ^c	F	9Y259D	124		X			56 (75/25)	21
12812	M	18Y207D	10	X				60 (86/14)	104
22699	F	1Y212D	6	X				230 (26/74)	55
22007	F	2Y351D	13	X				353 (92/8)	63
24059	M	1Y303D	3	X				408 (68/32)	0
24043	M	2Y180D	1	X					
24631	F	1Y225D	5	X					
22720	F	4Y203D	13	X				3 (100)	6
21282	F	6Y359D	32	X				9 (20/80)	7
18270	M	12Y38D	6	X				70 (25/75)	15
21255 ^d	M	8Y93D	0	X					
26174	M	2Y225D	4	X				650 (25/75)	168
27616	F	0Y217D	1	X				123 (61/39)	55
18276	M	14Y321D	6		X				
20482	M	11Y304D	13		X			37 (71/29)	14
28422	M	0Y276D	6				X	11 (80/20)	25
13221	X ^a	26Y49D	1		X				

*The clinical presentation of JMs with JME is similar to MS. Ataxia, paralysis or paresis of one or more limbs, and ocular abnormalities clinically characterizes JME.

^aX refers to a female pseudohermaphroditic animal.

^bAnimal 12068 had an initial episode of JME at 5 years 281 days and a second episode at 13 years 90 days.

^cAnimal 16749 had an initial episode at 9 years 212 days and a second episode at 10 years 18 days.

^dAnimal 21255 had an initial episode at 341 days and a second episode at 8 years 93 days. CSF = cerebrospinal fluid; JM = Japanese macaque; JME = Japanese macaque encephalomyelitis; MS = multiple sclerosis; ND = no data.

MRI abnormalities displayed here are similar to those of the other 5 cases of JME that underwent MRI, consistent with active neuroinflammation and similar to the MRI findings of acute lesions in MS.

Neuropathology

Complete necropsies were performed on 54 of 56 cases of JME. No monkeys had evidence of a systemic illness or acute disease outside of the CNS. In all cases, neuropathologic examination of the brain and cervical spinal cord revealed a multifocal demyelinating encephalomyeli-

tis. In most cases, multiple, dull, yellow-white to gray-tan, well-delineated plaques that ranged from 0.2 to 1.0cm in greatest dimension were apparent on gross inspection of postfixed coronal brain and spinal cord slices. Gross lesions were most frequent in the cerebellar white matter, brachium pontis, pyramids, and the white matter of the cervical spinal cord. A typical distribution of plaque-like lesions in the cerebellum and spinal cord was found in animal #19384 that underwent MRI (Fig 3A). Histologically, a majority of lesions seen in all JME cases had morphologic features consistent with the




FIGURE 2: MRI of animals with JME. (A–C) Postgadolinium T₁-weighted MRI images from JM #19384 11 days after presentation with acute flaccid paralysis of the right pelvic limb. (A) Coronal image of cerebral hemispheres reveals gadolinium-enhanced lesions (arrows) in the internal capsule. (B) Coronal image of posterior cerebral hemispheres, cerebellum, and brainstem shows 3 gadolinium-enhanced lesions in corpus medullare (arrows) of the cerebellum. (C) Sagittal image of upper cervical cord shows gadolinium-enhanced lesion (arrow). (D–I) Axial 3T MRI images from JM #26174 obtained 4 days after developing signs of JME. (D) Axial T₂-weighed image of upper cervical spinal cord shows hyperintense signal that is expanded in insert and identified (arrow). (E) Hyperintense signal in cerebellar region that is expanded in insert and denoted (arrow). The hyperintense ring surrounding “v” in the insert is CSF fluid superior to the 4th ventricle adjacent to the superior medullary velum. (F) Hyperintense signal in the genu of the corpus callosum that is expanded in the insert and identified (arrow). Axial postgadolinium T₁-weighted image shows enhancing lesions in (G) upper cervical spinal cord, (H) cerebellum, and (I) genu of the corpus callosum. (J–L) Axial 3T MRI images from JM #13221 during the acute phase of JME. (J) Axial T₂-weighted image shows hyperintense lesion in the left lateral pons and peduncle (arrow) that is hypointense on a (K) T₁-weighted precontrast MPAGE image (arrow). (L) The lesion enhances on a T₁-weighted MPAGE image acquired 30 minutes after the administration of 0.2mmol/kg gadoteridol (arrow). CSF = cerebrospinal fluid; JM = Japanese macaque; JME = Japanese macaque encephalomyelitis; MPAGE = magnetization prepared rapid acquisition gradient echo; MRI = magnetic resonance imaging.

chronic active plaques described in MS.^{13–17} Plaques were typically centered on venules or small veins. The chronic active plaques (see Fig 3B) were dominated centrally by macrophages engorged with myelin debris intermingled with astrocytes. Infiltrating macrophages and lymphocytes dominated in peripheral portions of plaques with focal concentrations of lymphocytes forming perivascular cuffs. Areas of necrosis and microcystic spaces were occasionally observed in the central portion of chronic-active lesions. Variations in lesion age were observed in some animals. Early lesions were infrequent and characterized by perivenous lymphocytic cuffs that frequently tracked perforating venules from pia-arachnoid

surfaces into adjacent white matter. The adjacent myelin was vesiculated and sparsely infiltrated with lymphocytes and macrophages. Rarely, small focal hemorrhages were encountered in the edematous myelin. Chronic inactive plaques composed principally of astrocytes and foamy macrophages were seen in many of the animals (see Fig 3C). Lymphocytes were largely absent in these lesions and silver staining revealed decreased numbers of axons with evidence of acute axotomies (see Fig 3D, E). Regardless of apparent age, lesions were exclusively located in white matter in all animals. Apart from rare, small, perivascular collections of lymphocytes, lesions were not seen in gray matter or the meninges. Transmission electron microscopy (EM) was performed on a limited number of lesions and these disclosed degenerating axons, demyelinated axons and occasional thinly myelinated axons, suggesting remyelination (data not shown).

Immunostaining was performed on 2 lesions localized by MRI in JM #13221. The first lesion was analyzed by immunostaining for alterations in MBP, NF, and olig2 immunoreactivity, and a second for infiltration of macrophages and T cells. MBP and NF labeling demonstrated areas with axon and myelin debris (defined as the demyelinated lesion) adjacent to border areas showing a mixture of intact and damaged fibers, which was,




FIGURE 3: Histopathology of JME. Histopathological examination of the brain of JM #19384 obtained 53 days following clinical presentation of JME. (A) Luxol fast blue-PAS-hematoxylin stain of cerebellum and cervical spinal cord. Note the large, well-defined, irregular-shaped areas of myelin loss in the corpus medullare of the cerebellum (arrows) corresponding to the lesions seen 42 days earlier in the MRI images (see Fig 2B). Similar lesions are present in the lateral white matter columns of the 1st, 2nd, and 5th cervical spinal cord segments (arrows); the abnormalities in the upper cervical cord correspond to lesions seen on MRI (see Fig 2C). Bar = 1cm. (B) High-power magnification of a portion of the large chronic active plaque in the upper left of the cerebellum. Normal appearance of white matter is obliterated by large foamy macrophages and scattered lymphocytes. Swollen myelin sheaths appear as circular, optically clear spaces. A portion of a thick perivascular lymphocytic cuff is present in the upper right of the panel. Hematoxylin-eosin stain; Bar = 50 μ m. (C) Portion of a chronic inactive plaque from the cerebellum. Note that the myelin in the upper portion of the panel is vesiculated but retains Luxol fast blue staining. Macrophages containing reddish PAS-stained debris and astrocytes obliterate normal white matter architecture in the bottom portion of the panel. Luxol fast blue-PAS-hematoxylin stain; Bar = 50 μ m. (D,E) Reduced number of axons in the center of (D) a chronic inactive plaque compared to (E) normal axonal density in normal appearing white matter. Bielschowsky's silver impregnation axonal stain; Bar = 50 μ m. JM = Japanese macaque; JME = Japanese macaque encephalomyelitis; MRI = magnetic resonance imaging; PAS = periodic acid-Schiff.





FIGURE 4: Demyelination and axonal loss in JME lesion. Immunofluorescent imaging from pontine lesion from JM #13221 identified by MRI (see Fig 2J–L). (A) The pontine lesion was double-labeled for MBP (green) and NF (red) to visualize demyelination and loss of neurons. Area to the right of the solid line demarcates demyelinated lesion and shows marked reduction in staining for MBP and NF, indicating loss of myelin and axons; dashed line is lesion border with mix of damaged myelin and normal appearing myelin. Area to the left of the dashed line is unaffected WM ($\times 5$ magnification). (B) High magnification images of the lesion, border, and unaffected white matter stained for the presence of MBP, NF, and DAPI for nuclei to visualize the extent of demyelination and axonal damage. Note reduction in MBP and NF staining in both the lesion and border areas. The merged image of lesion and border reveals increased cellularity (increased DAPI staining), some preserved myelinated axons and some NF+ axons without myelin. ($\times 40$ magnification). (C) A cerebellar lesion from JM #13221 showing CD68+ macrophages (red) and CD3+ T cells (green) near a venule (blue) ($\times 10$ and $\times 20$ magnification, respectively). (D) The lesion site in A was immunostained for olig2 to assess the presence of oligodendrocytes and with a nuclear stain (DAPI) in the lesion, border, and unaffected WM. Note the reduction in staining in the sections from the lesion and border areas for olig2 with increased numbers of DAPI+ cells ($\times 40$ magnification). (E) Quantification of olig2 immunolabeling. Three adjacent sections were analyzed and 3 random fields in each section were counted at the lesion, lesion border, and in adjacent WM, showing significant reduction in olig2+ cells in the lesion and border compared with normal WM ($p < 0.01$). DAPI = 4,6'-Diamino-2-phenylindole dihydrochloride; JM = Japanese macaque; JME = Japanese macaque encephalomyelitis; MBP = myelin basic protein; MRI = magnetic resonance imaging; NF = neurofilament; WM = white matter.



in turn, adjacent to unaffected white matter (Fig 4A, B). Staining for the presence of CD68 in a lesion located in the cerebellum revealed numerous CD68+ macrophages and perivascular CD3+ T cells (see Fig 4C). Oligodendrocytes were quantified by enumerating olig2-labeled cells within the lesion shown in Figure 4A and B. There was nearly complete absence of olig2 immunoreactivity within the lesion and a dramatic reduction in olig2+ cells at the lesion border compared to adjacent unaffected white matter (see Fig 4D, E). The lesions of JME thus are multifocal, contain T cell and macrophage infiltrates, and reveal demyelination, loss of oligodendrocytes, limited remyelination, and axonal degeneration.

Isolation of Novel Gamma-2 Herpesvirus from Encephalomyelitis Lesions

As viral infection has been associated with inflammatory demyelination in mice, we investigated whether a virus might be present in acute lesions of animals with JME. Explant cultures of lesioned spinal cord tissue vs normal

neuronal tissue from JM #17792 layered over primary rhesus fibroblasts yielded an infectious agent that was identified by transmission EM as a herpesvirus (data not shown). The virus isolate was subsequently passaged and viral DNA purified from cell-free virions for degenerate polymerase chain reaction (PCR) amplification over a highly conserved region of the viral DNA polymerase to identify the virus. Preliminary DNA sequence analysis revealed the virus was most similar to rhesus macaque rhadinovirus (RRV). The complete sequence of the viral genome was determined and compared to simian and human herpesvirus genomes representing alpha-herpesviruses, beta-herpesviruses and gamma-1 and gamma-2 herpesviruses. By this analysis, the JM herpesvirus, referred to as JM rhadinovirus (JMRV) is a gamma-2 herpesvirus most closely related to RRV, with 89.5% nucleotide sequence identity and secondarily related to human Kaposi sarcoma-associated herpesvirus (KSHV) with 47.9% nucleotide sequence identity (Table 2). JMRV has subsequently been isolated from active CNS lesions of 5 other JM with JME, but has not been isolated from normal white matter from JM with or without JME.

Discussion

JME appeared spontaneously in JM at the ONPRC 21 years after the colony was established. The initial case of JME occurred in 1986 and since then the disease typically has affected 1% to 3% of the colony each year, with 2 exceptions. JME usually occurs in young adult animals, but the disease can present in juvenile or aged animals, and shows no preference for either gender. Clinically, JME causes paralysis, ataxia, and ocular motor paresis. While most animals failed to recover sufficiently to be safely returned to the colony, 3 monkeys recovered, were returned to the colony, and then relapsed 1 or more years later. MRI of 8 animals revealed changes similar to acute MS. Pathologically, JME causes multifocal areas of demyelination of varying acuity with loss of oligodendrocytes and variable axonal loss in the white matter of the cerebrum, cerebellum, brainstem, and spinal cord associated with macrophages and lymphocytic infiltrates. Chronic inactive demyelinated lesions also occur, suggesting that asymptomatic lesions may occur before clinical JME. JME is the first naturally occurring inflammatory demyelinating disease in an NHP.

JME has clinical, MRI, and pathologic similarities to MS. These include similar clinical manifestations, a relapsing course in monkeys that recovered sufficiently to be returned to the colony, MRI abnormalities like those of acute MS lesions and similar neuropathologic abnormalities, including plaque-like demyelinating lesions

TABLE 2: Clustal W Alignment of JMRV Genome with Select Simian and Human Herpesvirus Genomes Showing Percent Nucleotide Sequence Identity

Virus	JMRV	RRV	KSHV	HVS	RhLCV	EBV	RhCMV	HHV-6A	HHV-6B	HB virus	SVV	HSV-1
JMRV	100	89.5	47.9	35.0	27.9	22.3	19.5	27.2	26.2	27.1	31.3	25.6
RRV	89.5	100	48.3	34.7	28.3	22.6	19.9	27.6	26.5	27.6	31.5	26.1
KSHV	47.9	48.3	100	32.3	27.3	22.2	19.5	26.7	25.7	27.3	29.3	26.1
HVS	35.0	34.7	32.3	100	20.2	19.4	15.9	23.5	22.8	18.6	30.7	19.4
RhLCV	27.9	28.3	27.3	20.2	100	53.1	23.2	26.1	25.1	28.3	21.7	25.8
EBV	22.3	22.6	22.2	19.4	53.1	100	23.1	22.0	21.3	23.2	20.5	22.7
RhCMV	19.5	19.9	19.5	15.9	23.2	23.1	100	22.3	22.6	20.0	17.0	18.9
HHV-6A	27.2	27.6	26.7	23.5	26.1	22.0	22.3	100	88.3	25.2	24.6	24.0
HHV-6B	26.2	26.5	25.7	22.8	25.1	21.3	22.6	88.3	100	25.0	23.7	23.7
HB virus	27.1	27.6	27.3	18.6	28.3	23.2	20.0	25.2	25.0	100	21.4	49.5
SVV	31.3	31.5	29.3	30.7	21.7	20.5	17.0	24.6	23.7	21.4	100	21.9
HSV-1	25.6	26.1	26.1	19.4	25.8	22.7	18.9	24.0	23.7	49.5	21.9	100

EBV = Epstein Barr virus (GenBank accession number V01555); HB virus = herpes B virus (GenBank accession number NC_004812); HHV-6A = human herpesvirus 6A (GenBank accession number NC_001664); HHV-6B = human herpesvirus 6B (GenBank accession number AF157706); HSV-1 = herpes simplex virus type 1 strain F (GenBank accession number GU734771); HVS = Herpesvirus saimiri (GenBank accession number NC_001350); JMRV = Japanese macaque rhadinovirus (GenBank accession number AY528864.1); KSHV = Kaposi sarcoma-associated herpesvirus (GenBank accession number U75698); RhCMV = rhesus cytomegalovirus (GenBank accession number NC_006150); RhLCV = rhesus lymphocryptovirus (GenBank accession number AY037858); RRV = rhesus macaque rhadinovirus (GenBank accession number AF083501); SVV = simian varicella virus (GenBank accession number NC_002686).

associated with lymphocytes and macrophages, oligodendrocyte depletion, limited remyelination, and variable axonal loss. However, there are some features of JME that differ from MS. These include CSF containing neutrophils as well as lymphocytes in most cases and necrosis and hemorrhage as part of the pathologic continuum. These differences may represent species-specific differences in inflammatory and tissue responses. It is worth noting that EAE in NHP often has neutrophils in the CSF and necrosis and hemorrhage as part of the neuropathology, which differs from EAE in rodents.¹⁸ Overall the clinical, MRI and neuropathologic features of JME have more similarities than differences with MS and JME is clearly an inflammatory demyelinating disease. Further investigations are needed to determine the full extent of similarities of JME with MS.

There are several features of JME that makes this an extremely appealing model for MS. First, the disease occurs spontaneously, which makes it distinct from current models of MS that require artificial manipulation to induce disease. Second, it affects a small percentage of animals in the colony, approximately 1% to 3% each year, suggesting there may be a genetic susceptibility to the disease as there is in MS. The ONPRC began tracing

the pedigrees of the JM troop in 2000 utilizing specific microsatellite markers. Interestingly, animals developing JME since 2000 come from distinct matrilineal lines from the original troop, supporting the idea that host genetic factors play a significant part in susceptibility to disease (unpublished data). Determining the genetic factors that coincide with disease and predispose animals to develop JME is currently being explored on archived tissue and new cases. Third, like MS, JME is an inflammatory disease, suggesting either an autoimmune disease or a viral infection. An autoimmune pathogenesis of MS is commonly proposed but definitive evidence of this remains lacking. Autoreactive T cells and anti-myelin antibodies have been proposed as being critical to the immunopathogenesis of MS.^{19–21} We are currently assessing new cases of JME for anti-myelin T cell responses and antibodies against myelin antigens.

Finally, based on epidemiologically studies and the histopathology, a viral etiology for MS has long been suspected. Multiple candidate viruses have been proposed but none has been convincingly associated with the disease. Here, we report the isolation of a previously unknown herpesvirus, JMRV, isolated from acute JME

lesions. We have been unable to isolate JMRV from normal appearing white matter of JM with and without JME. Complete DNA sequencing reveals this to be a rhadinovirus with significant sequence homologies with RRV and human KSHV. Reagents are being generated against this virus to evaluate the potential role of JMRV in JME. This is of particular interest since human Epstein-Barr virus and human herpesvirus 6 are 2 herpesviruses that have been implicated as playing a role in the pathogenesis of MS.^{22–30} Demonstrating that a simian rhadinovirus induces JME will provide a new class of herpesvirus that would warrant investigation in MS.

In summary, JME is a unique spontaneous demyelinating disease in an NHP. Preliminary results suggest that the disease occurs in genetically predisposed monkeys and is associated with a novel simian herpesvirus. Further investigation of the pathogenesis of JME may provide new insights into the pathogenesis of MS.

Acknowledgments

This research was supported by the National Institutes of Health (NIH/NCRR) Grant P51RR00163 (MKA, SGK, LSS, SWW), the Research Enrichment Award Program of the Department of Veterans Affairs Biomedical Laboratory Research and Development (DNB), the OHSU Multiple Sclerosis Center, the United States Department of Defense (W81XWH-09-1-0276) (LSS, SGK, WDR, SWW), OHSU/Vertex SRA-05-07-01 (WDR) and NIH/NIBIB Grant R01-EB007258 (WDR).

We thank L. Boshears and A. Townsend for assistance with the manuscript and figures, and members of the Division of Animal Resources for their diligence and care of the animals.

Potential Conflicts of Interest

W.D.R. received grants from Vertex Pharmaceuticals and has stock/stock options from DeltaPoint, Inc.

References

1. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. *N Engl J Med*. 2000;343:938–952.
2. Libbey J, Fujinami R. Potential triggers of MS. In: Martin R, Lutterotti A, eds. *Molecular Basis of Multiple Sclerosis*. Berlin/Heidelberg: Springer, 2010:21–42.
3. Libbey JE, Fujinami RS. Experimental autoimmune encephalomyelitis as a testing paradigm for adjuvants and vaccines. *Vaccine* 2011;29:3356–3362.
4. Ferraro A, Cazzullo CL. Chronic experimental allergic encephalomyelitis in monkeys. *J Neuropathol Exp Neurol* 1948;7: 235–260.

5. Genain CP, Hauser SL. Creation of a model for multiple sclerosis in *Callithrix jacchus* marmosets. *J Mol Med* 1997;75:187–197.
6. Rivers TM, Schwentker FF. Encephalomyelitis accompanied by myelin destruction experimentally produced in monkeys. *J Exp Med* 1935;61:689–702.
7. 't Hart BA, Massacesi L. Clinical, pathological, and immunologic aspects of the multiple sclerosis model in common marmosets (*Callithrix jacchus*). *J Neuropathol Exp Neurol* 2009;68: 341–355.
8. Miller SD, Vanderlugt CL, Begolka WS, et al. Persistent infection with Theiler's virus leads to CNS autoimmunity via epitope spreading. *Nat Med* 1997;3:1133–1136.
9. Tsunoda I, Fujinami RS. Two models for multiple sclerosis: experimental allergic encephalomyelitis and Theiler's murine encephalomyelitis virus. *J Neuropathol Exp Neurol* 1996;55: 673–686.
10. Dal Canto MC, Lipton HL. Multiple sclerosis. Animal model: Theiler's virus infection in mice. *Am J Pathol* 1977;88:497–500.
11. Clatch RJ, Melvold RW, Dal Canto MC, Miller SD, Lipton HL. The Theiler's murine encephalomyelitis virus (TMEV) model for multiple sclerosis shows a strong influence of the murine equivalents of HLA-A, B, and C. *J Neuroimmunol* 1987;15:121–135.
12. Wong SW, Bergquam EP, Swanson RM, et al. Induction of B cell hyperplasia in simian immunodeficiency virus-infected rhesus macaques with the simian homologue of Kaposi's sarcoma-associated herpesvirus. *J Exp Med* 1999;190:827–840.
13. Kornek B, Storch MK, Weissert R, et al. Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. *Am J Pathol* 2000;157:267–276.
14. Prineas JW. The neuropathology of multiple sclerosis. In: Koetsier JC (ed). *Handbook of Clinical Neurology*. Amsterdam: Elsevier, 1985:213–222.
15. Raine CS. Demyelinating diseases. In: (2nd ed.) Davis RL, Robertson DM (Editors). *Textbook of Neuropathology*. Baltimore, MD: Williams and Wilkins, 1990:468–547.
16. Lucchinetti CF, Bruck W, Rodriguez M, Lassmann H. Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis. *Brain Pathol* 1996;6:259–274.
17. Ozawa K, Suchanek G, Breitschopf H, et al. Patterns of oligodendroglia pathology in multiple sclerosis. *Brain* 1994;117(Pt 6): 1311–1322.
18. Shaw CM, Alvord EC Jr. Treatment of experimental allergic encephalomyelitis in monkeys. II. Histopathological studies. In: Shiraki H, Yonezawa T, Kuroiwa Y, eds. *The Aetiology and Pathogenesis of the Demyelinating Diseases*. Tokyo: Japan Science Press, 1976:277–295.
19. Genain CP, Cannella B, Hauser SL, Raine CS. Identification of autoantibodies associated with myelin damage in multiple sclerosis. *Nat Med* 1999;5:170–175.
20. Diaz-Villoslada P, Shih A, Shao L, Genain CP, Hauser SL. Autoreactivity to myelin antigens: myelin/oligodendrocyte glycoprotein is a prevalent autoantigen. *J Neuroimmunol* 1999;99: 36–43.
21. Koehler NK, Genain CP, Giesser B, Hauser SL. The human T cell response to myelin oligodendrocyte glycoprotein: a multiple sclerosis family-based study. *J Immunol* 2002;168:5920–5927.
22. Alvarez-Lafuente R, Martin-Estefania C, de Las Heras V, et al. Active human herpesvirus 6 infection in patients with multiple sclerosis. *Arch Neurol* 2002;59:929–933.
23. Ascherio A. Epstein-Barr virus in the development of multiple sclerosis. *Expert Rev Neurother*. 2008;8:331–333.
24. Ascherio A, Munch M. Epstein-Barr virus and multiple sclerosis. *Epidemiology* 2000;11:220–224.

25. Ascherio A, Munger KL, Lennette ET, et al. Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective study. *JAMA* 2001;286:3083–3088.
26. Carrigan DR, Harrington D, Knox KK. Subacute leukoencephalitis caused by CNS infection with human herpesvirus-6 manifesting as acute multiple sclerosis. *Neurology* 1996;47:145–148.
27. Carrigan DR, Knox KK. Human herpesvirus six and multiple sclerosis. *Mult Scler* 1997;3:390–394.
28. Cepok S, Zhou D, Srivastava R, et al. Identification of Epstein-Barr virus proteins as putative targets of the immune response in multiple sclerosis. *J Clin Invest* 2005;115:1352–1360.
29. Challoner PB, Smith KT, Parker JD, et al. Plaque-associated expression of human herpesvirus 6 in multiple sclerosis. *Proc Natl Acad Sci U S A* 1995;92:7440–7444.
30. Christensen T. The role of EBV in MS pathogenesis. *Int MS J* 2006;13:52–57.